Advancement to clinical trials with STAM
- NEWS RELEASE
Selecting models with high clinical correlation is essential for successful drug development.
Based on the results of non-clinical studies using our proprietary STAMTM model (NASH-HCC model), 15 test substances have advanced to clinical trials so far.
Some of these clients who have progressed their compounds to clinical trials are listed in the table below.
|Novartis||Tropifexor||FXR agonist||--||Phase II b|
|BMS||BMS-986036||FGF21- analog||--||Phase II a|
|Albireo||Elobixibat||IBAT- inhibitor||--||Phase II|
|Boehringer Ingelheim||BI 1467335||SSAO/VAP- 1 inhibitor||Pharmaxis||Phase II a|
|Gilead||GS-9674||FXR agonist||Phenex Pharmaceuticals||Phase II a|
|Allergan||Cenicriviroc||CCR2/ CCR5 dual inhibitor||Tobira Pharmaceuticals||Phase III|
As a highly clinically relevant model, the STAMTM model provided by SMC Laboratories reproduces the following pathologies.
- Hepatocyte ballooning, a characteristic pathological feature of human NASH
- Burned-out NASH, in which lipid droplets decrease as fibrosis progresses
- Accumulation of fibrosis around the central vein
- Mild elevation of ALT, a liver injury marker
- Increase in NASH markers such as CK-18
- Increased human HCC markers glutamine synthase, glypican-3 and AFP
Please feel free to contact us for details on our models and services.
About SMC Laboratories, Inc.
SMC Laboratories is a Tokyo-based, non-clinical CRO specialized in inflammatory and fibrotic diseases.
We offer pharmacological studies and histopathological analysis services using reproducible and stable disease mouse models, including our proprietary STAMTM model (NASH-HCC model).
Utilizing our broad knowledge and expertise in inflammation and fibrosis, we support drug development through tailor-made programs that flexibly meet the needs of clients.
SMC Laboratories, Inc.